InspireMD receives FDA approval for CGuard Prime, re‑enters U.S. market amid Q3 loss
InspireMD announced FDA clearance of its CGuard Prime TransCarotid Stent System for TCAR procedures, allowing the company to resume sales in the United States. The Q3 2026 earnings call reported total revenue of $2.2 million, an 11% year‑over‑year decline, while international revenue grew about 9% year‑over‑year to $2.2 million. The company posted a net loss of $9.8 million, or $0.12 per share, and said cash and cash equivalents stood at $19.2 million. Management highlighted a 27% reduction in operating expenses and a 40,000‑procedure expansion of the U.S. addressable market.
Why it matters
The FDA approval creates a new revenue stream in the U.S., potentially adding roughly 40,000 annual TCAR procedures, but the company remains cash‑constrained and posted a sizable loss, indicating short‑term financial pressure. The cash balance of $19.2 million and the 27% expense cut provide limited runway for commercial rollout.
Key facts
- 1Q3 2026 total revenue was $2.2 million, down 11% year‑over‑year (reported). tipranks.com
- 2International revenue grew about 9% year‑over‑year to $2.2 million (reported). tipranks.com
- 3International revenue grew 10% on a constant‑currency basis. tipranks.com
- 4Net loss was $9.8 million, or $0.12 per basic and diluted share (reported). tipranks.com
- 5Cash and cash equivalents were $19.2 million as of September 30, 2026 (reported). finance.yahoo.com
- 6Operating expenses fell to $10.2 million, a 27% reduction from $13.9 million a year earlier (reported). tipranks.com
Summary written by AlphAI AI Desk from 7 of 7 sources. Not investment advice. Figures are as stated by the linked sources.